Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Anna-Maija Vuorela"'
Autor:
T. Luukkaala, R. Jolanki, Kristiina Alanko, Taina Hasan, Rauno J. Harvima, K. Lammintausta, Riitta Riekki, Arto Lahti, Antti Lauerma, Kirsti Kalimo, Tapio Rantanen, K. Turjanmaa, E. Varjonen, Arja Laukkanen, Anna-Maija Vuorela
Publikováno v:
Contact Dermatitis. 53:40-45
Contact sensitivity to cosmetics is common, but the sensitizing chemicals vary between countries and study periods. The present survey aimed at revealing the recent trends in patch test sensitivity with cosmetic chemicals in Finland. We report a retr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad4e59bd3b2374450804d0b63dbf3395
https://doi.org/10.1111/j.0105-1873.2005.00630.x
https://doi.org/10.1111/j.0105-1873.2005.00630.x
Autor:
Kristiina Turjanmaa, Aila Niinimäki, Tapio Rantanen, Kristiina Aalto-Korte, Matti Hannuksela, Antti Lauerma, Lasse Kanerva, Kirsti Kalimo, M. Horsmanheimo, Tuula Estlander, Arto Lahti, Riita Jolanki, Anna-Maija Vuorela, Kaija Lammintausta, Rauno J. Harvima, Taina Hasan
Publikováno v:
American Journal of Contact Dermatitis. 12:83-87
Background: Dental products contain many allergens, and may cause problems both for patients undergoing dental treatment and for dental personnel because of occupational exposure. Individual patch test clinics may not study sufficient numbers of pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b75b48f6af17391024e24894ca71210
https://doi.org/10.1097/01634989-200106000-00004
https://doi.org/10.1097/01634989-200106000-00004
Autor:
Riitta Riekki, Kaija Lammintausta, Leena Ackermann, Tapio Rantanen, Kristiina Alanko, Jussi Liippo, Kristiina Aalto-Korte, Riitta Jolanki, Arja Laukkanen, Taina Hasan, Anna-Maija Vuorela, Antti Lauerma
Publikováno v:
Contact dermatitis. 64(1)
Summary Background. Antimicrobials constitute the second most common cause of contact allergy to cosmetics. Methylisothiazolinone (MI), previously always used together with methylchloroisothiazolinone (MCI), has recently been approved in the EU for u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ada81eaff81d90345522d133f985fca
https://pubmed.ncbi.nlm.nih.gov/21166817
https://pubmed.ncbi.nlm.nih.gov/21166817